{"doi":"10.1093/hropen/hoae065","title":"Evidence-based guideline: premature ovarian insufficiency,","abstract":"STUDY QUESTION: How should premature/primary ovarian insufficiency (POI) be diagnosed and managed based on the best available evidence from published literature? SUMMARY ANSWER: The current guideline provides 145 recommendations on symptoms, diagnosis, causation, sequelae, and treatment of POI. WHAT IS KNOWN ALREADY: Premature ovarian insufficiency (POI) presents a significant challenge to women's health, with far-reaching implications, both physically and emotionally. The potential implications include adverse effects on quality of life; fertility; and bone, cardiovascular, and cognitive health. Although hormone therapy (HT) can mitigate some of these effects, many questions still remain regarding the optimal management of POI. STUDY DESIGN SIZE DURATION: The guideline was developed according to the structured methodology for development of ESHRE guidelines. Key questions were determined by a group of experts and informed by a scoping survey of women and health care professionals. Literature searches and assessments were then performed. Papers published up to 30 January 2024 and written in English were included in the guideline. An integrity review was conducted for the randomized controlled trials (RCTs) on POI included in the guideline. PARTICIPANTS/MATERIALS SETTING METHODS: Based on the collected evidence, recommendations were formulated and discussed within the guideline development group until consensus was reached. Women with lived experience of POI informed the recommendations in general, and particularly on those on provision of care. A stakeholder review was organized after finalization of the draft. The final version was approved by the guideline development group and the ESHRE Executive Committee. MAIN RESULTS AND THE ROLE OF CHANCE: New data indicate a higher prevalence of POI, 3.5%, than was previously thought. This guideline aims to help health care professionals to apply best practice care for women with POI. The recent update of the POI guideline covers 40 clinical questions on diagnosis of the condition, the different sequelae, including bone, cardiovascular, neurological and sexual function, fertility and general well-being, and treatment options, including HT. The list of clinical questions was expanded from the previous iteration of the guideline (2015) based on the scoping survey and appreciation of emerging knowledge of POI. Questions were added on the role of anti-Müllerian hormone (AMH) in the diagnosis of POI, fertility preservation, muscle health, and specific considerations for HT in iatrogenic POI. Additionally, the topic on complementary treatments was extended with specific focus on non-hormonal treatments and lifestyle management options. Significant changes from the previous 2015 guideline include the recommendations that only one elevated FSH >25 IU is required for diagnosis of POI, and guidance that AMH testing, repeat FSH measurement, and/or AMH may be required where there is diagnostic uncertainty. Recommendations were also updated regarding genetic testing, estrogen doses and regimens, use of the combined oral contraceptive and testosterone therapy. Women with lived experience of POI informed the recommendations on provision of care. LIMITATIONS REASONS FOR CAUTION: The guideline describes different management options, but it must be acknowledged that for most of these options, supporting evidence is limited for POI. WIDER IMPLICATIONS OF THE FINDINGS: The guideline provides health care professionals with clear advice on best practice in POI care, based on the best evidence currently available. In addition, a list of research recommendations is provided to guide further studies in POI. STUDY FUNDING/COMPETING INTERESTS: The guideline was developed and funded by ESHRE, American Society for Reproductive Medicine (ASRM), Centre for Research Excellence in Women's Health in Reproduction Life (CRE-WHiRL), and International Menopause Society (IMS), covering expenses associated with the guideline","journal":"Human Reproduction Open","year":2024,"id":416470,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":134,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9668,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":301099,"name":"Richard A. Anderson","orcid":"0000-0002-7495-518X","position":1,"is_corresponding":false},{"id":1074391,"name":"Amy Bennie","orcid":"0000-0002-1819-7994","position":2,"is_corresponding":false},{"id":247242,"name":"Marcelle I. Cedars","orcid":"0000-0003-3682-6907","position":3,"is_corresponding":false},{"id":1199838,"name":"Melanie Davies","orcid":"0000-0001-6907-5527","position":4,"is_corresponding":false},{"id":1199839,"name":"Carolyn Ee","orcid":"0000-0002-3363-9199","position":5,"is_corresponding":false},{"id":337387,"name":"Claus Højbjerg Gravholt","orcid":"0000-0001-5924-1720","position":6,"is_corresponding":false},{"id":1199840,"name":"Sophia Kalantaridou","orcid":"0000-0002-0590-1575","position":7,"is_corresponding":false},{"id":396813,"name":"Amanda N. Kallen","orcid":"0000-0003-0118-3251","position":8,"is_corresponding":false},{"id":1200731,"name":"Kimberly Q Kim","orcid":null,"position":9,"is_corresponding":false},{"id":1199841,"name":"Micheline Misrahi","orcid":"0000-0002-5379-8859","position":10,"is_corresponding":false},{"id":1052785,"name":"Aya Mousa","orcid":"0000-0002-7356-4523","position":11,"is_corresponding":false},{"id":1199842,"name":"Rossella E. Nappi","orcid":"0000-0003-1713-6396","position":12,"is_corresponding":false},{"id":17537,"name":"Walter A. Rocca","orcid":"0000-0002-1832-7664","position":13,"is_corresponding":false},{"id":423658,"name":"Xiangyan Ruan","orcid":"0000-0001-7777-247X","position":14,"is_corresponding":false},{"id":471155,"name":"Helena Teede","orcid":"0000-0001-7609-577X","position":15,"is_corresponding":false},{"id":916677,"name":"Nathalie Vermeulen","orcid":"0000-0001-8046-6799","position":16,"is_corresponding":false},{"id":732477,"name":"Elinor Vogt","orcid":"0000-0001-9810-987X","position":17,"is_corresponding":false},{"id":1199843,"name":"Amanda Vincent","orcid":"0000-0002-3760-7266","position":18,"is_corresponding":false},{"id":1200732,"name":"ESHRE, ASRM, CREWHIRL, and IMS Guideline Group on POI","orcid":null,"position":19,"is_corresponding":false},{"id":1199844,"name":"Ladan Yeganeh","orcid":"0000-0003-3413-152X","position":20,"is_corresponding":false},{"id":1200733,"name":"Rinky Giri","orcid":null,"position":21,"is_corresponding":false},{"id":1199845,"name":"M. Flanagan","orcid":"0000-0002-2377-4995","position":22,"is_corresponding":false},{"id":1021687,"name":"Nick Panay","orcid":"0000-0001-6662-1334","position":0,"is_corresponding":true}],"reference_count":6,"raw_metadata":null,"created_at":"2026-07-19T01:56:20.964471Z","pmid":"39660328","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}